Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling
Open Access
- 21 April 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 7 (4), e2201
- https://doi.org/10.1038/cddis.2015.324
Abstract
Galectin-1 (Gal-1) is involved in several pathological activities associated with tumor progression and chemoresistance, however, the role and molecular mechanism of Gal-1 activity in hepatocellular carcinoma (HCC) epithelial–mesenchymal transition (EMT) and sorafenib resistance remain enigmatic. In the present study, forced Gal-1 expression promoted HCC progression and sorafenib resistance. Gal-1 elevated αvβ3-integrin expression, leading to AKT activation. Moreover, Gal-1 overexpression induced HCC cell EMT via PI3K/AKT cascade activation. Clinically, our data revealed that Gal-1 overexpression is correlated with poor HCC survival outcomes and sorafenib response. These data suggest that Gal-1 may be a potential therapeutic target for HCC and a biomarker for predicting response to sorafenib treatment.Keywords
This publication has 33 references indexed in Scilit:
- Galectin-1 Upregulates CXCR4 to Promote Tumor Progression and Poor Outcome in Kidney CancerJournal of the American Society of Nephrology, 2014
- Integrin β3 links therapy resistance and cancer stem cell propertiesNature, 2014
- An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibitionNature, 2014
- Unraveling galectin-1 as a novel therapeutic target for cancerCancer Treatment Reviews, 2014
- MEK in cancer and cancer therapyPharmacology & Therapeutics, 2014
- Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancerCell Death & Disease, 2014
- Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular CarcinomaGastroenterology, 2013
- Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinomaHepatology, 2012
- The evasive promise of antiangiogenic therapyJournal of Hepatology, 2009
- Hepatocellular carcinoma: Current management and future trendsGastroenterology, 2004